Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicASX:VLA
Date3/2009
Raised
Post IPO Valuation

General Information

Websiteviralytics.com
CategoryBioTech
Phone+61 (0)2 9988 4000
Emailinvestorrelations...
Employees

Offices

Sydney, AUS
Suite 305, Level 3
66 Hunter Street, New South Wales,
Sydney, 2000, AUS

Funding

TOTAL $27M
POST IPO FUNDING TOTAL $27M
Post IPO Equity, 3/2014
$27M

Tags

Viralytics

Viralytics is an Australian biotechnology company, listed on the Australian Stock Exchange (ASX:VLA) and is quoted on the OTC market (VRACY). Focused on developing oncolytic virotherapy for the treatment of a wide range of cancers Viralytics’ headquarters are in Sydney, Australia and research and operations are in Newcastle, Australia.

Oncolytic virotherapy makes use of the cancer destroying capabilities of a range of benign viruses. The potential of oncolytic virotherapy is the ability to treat cancers more effectively and with minimum side-effects.

Recent Milestones

  • Dollar
    Viralytics received $27M in Post IPO Equity funding. (3/13/14)
    Posted 1/30/14 at 8:44pm via biospace.com
  • Stock
    Went public with stock symbol ASX:VLA. (3/9/09)
    Posted 1/30/14 at 8:44pm

Videos

Screenshots

Viralytics screenshot
Above: Viralytics Screenshot -- #1
Uploaded: 1/31/14

Stock Price

Sources

  1. Viralytics Ltd (VLA.AX) Completes $27 Million Fund Raising (biospace.com) [edit]
Edit This Page
Last Edited 3/28/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy